REZENOPY™ Naloxone Spray Secures GPO Access to 60% of U.S. Institutional Market
SCNX sits 30% above its 52-week low of $0.372 on light trading volume (0.1× avg).
Summary
Scienture Holdings has significantly expanded commercial access for its REZENOPY™ (naloxone HCl) Nasal Spray 10 mg by formalizing multiple Group Purchasing Organization (GPO) agreements. These agreements provide access to over 5,000 healthcare institutions, including hospitals, clinics, and nursing homes, potentially penetrating approximately 60% of the U.S. institutional market. This also broadens reach to first responders, EMS providers, and rehabilitation centers. For a company with a modest market cap, securing such broad institutional access for its highest-dose FDA-approved naloxone product, which targets a $141 million annual market, is a material commercialization milestone. This move is expected to drive significant adoption and strengthen the company's revenue growth trajectory.
At the time of this announcement, SCNX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8M. The 52-week trading range was $0.37 to $3.17. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.